Recent breakthroughs in the management of locally advanced and recurrent/metastatic cervical cancer

J Gynecol Oncol. 2023 Nov 30. doi: 10.3802/jgo.2024.35.e30. Online ahead of print.ABSTRACTCervical cancer continues to be a global threat affecting individuals in resource poor communities disproportionately. The treatment paradigm for this disease is ever evolving with recent innovations propelling oncologic outcomes to a new frontier offering survival benefits for patients struggling with locally advanced disease and metastatic/recurrent carcinoma. Immunologic checkpoint inhibitors and anti-body drug conjugates represent two novel drug classes that have demonstrable activity in this disease, particularly in the first-line and second-line treatment paradigm for recurrence. The tolerability of these novel medicines and associated durable responses underscore regulatory approval by the U.S. Food and Drug Administrations and their implementation in clinic.PMID:38072400 | DOI:10.3802/jgo.2024.35.e30
Source: Journal of Gynecologic Oncology - Category: OBGYN Authors: Source Type: research